药物发现
异源表达
生物
计算生物学
基因
异源的
合成生物学
基因表达
遗传学
生物信息学
重组DNA
作者
Colin J. B. Harvey,Man‐Cheng Tang,Ulrich Schlecht,Joe Horecka,Curt R. Fischer,Hsiao‐Ching Lin,Jian Li,Brian Naughton,James Cherry,Molly Miranda,Yong Fuga Li,Angela Chu,James R. Hennessy,Gergana A Vandova,Diane O. Inglis,Raeka S. Aiyar,Lars M. Steinmetz,Ronald W. Davis,Marnix H. Medema,Elizabeth S. Sattely
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2018-04-11
卷期号:4 (4): eaar5459-eaar5459
被引量:256
标识
DOI:10.1126/sciadv.aar5459
摘要
For decades, fungi have been a source of U.S. Food and Drug Administration-approved natural products such as penicillin, cyclosporine, and the statins. Recent breakthroughs in DNA sequencing suggest that millions of fungal species exist on Earth, with each genome encoding pathways capable of generating as many as dozens of natural products. However, the majority of encoded molecules are difficult or impossible to access because the organisms are uncultivable or the genes are transcriptionally silent. To overcome this bottleneck in natural product discovery, we developed the HEx (Heterologous EXpression) synthetic biology platform for rapid, scalable expression of fungal biosynthetic genes and their encoded metabolites in Saccharomyces cerevisiae. We applied this platform to 41 fungal biosynthetic gene clusters from diverse fungal species from around the world, 22 of which produced detectable compounds. These included novel compounds with unexpected biosynthetic origins, particularly from poorly studied species. This result establishes the HEx platform for rapid discovery of natural products from any fungal species, even those that are uncultivable, and opens the door to discovery of the next generation of natural products.
科研通智能强力驱动
Strongly Powered by AbleSci AI